Zusammenfassung
Die Einschätzung des Infektionsrisikos von Patienten mit rheumatologischen Erkrankungen basiert auf der sorgfältigen Erfassung der hierfür relevanten Faktoren wie der Grunderkrankung selbst, der Intensität der immunsuppressiven Therapie und der Schwere etwaiger Komorbiditäten. Aus infektiologischer Sicht sind hier besonders das wiederholte Auftreten schwerer Infektionen sowie Vorerkrankungen wie eine latente Tuberkulose oder eine chronische Hepatitis B oder C zu erwähnen. Dies kann eine prophylaktische antibiotische Therapie erforderlich machen, die ansonsten vermieden werden sollte, um nicht auf resistente Erreger zu selektionieren. Weiterhin sind Impfungen besonders geeignet das Risiko für häufige Infektionskrankheiten spezifisch zu minimieren.
Abstract
The individual risk assessment concerning infections in patients with rheumatic diseases is based on the detailed personalized documentation of relevant risk factors, such as the underlying disease itself, the intensity of immunosuppressive therapy and the severity of any comorbidities. From the perspective of infectiology, the history of repeated and severe infections as well as previous illnesses, such as (latent) tuberculosis and chronic hepatitis B or C need to be considered. In some instances prophylactic antibiotic therapy might be required, which should otherwise be avoided in order to prevent selection of resistant pathogens. Furthermore, vaccinations are particularly suitable to specifically minimize the risk for frequent infectious diseases.
Literatur
Gavazzi G, Krause KH (2002) Ageing and infection. Lancet Infect Dis 2(11):659–666 (Nov)
Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C (2013) Arthritis Care Res 65(3):353–361
Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T, Gross FL, Steward-Clark E, Cao W, Jefferson S, Veguilla V, Gillis E, Meece J, Bai Y, Tatum H, Hancock K, Stevens J, Spencer S, Chen J, Gargiullo P, Braun E, Griffin MR, Sundaram M, Belongia EA, Shay DK, Katz JM, Sambhara S (2015) Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses. Open Forum Infect Dis 15;2(2):ofv52 (Apr)
Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Shay DK, Sambhara S (2012) Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population. Aging Dis 3(1):68–90 (Epub 2011 Sep 30.)
Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46(9):2294–2300 (Sep)
Hellmich B (2017) Current guidelines on ANCA-associated vasculitides: Common features and differences. Z Rheumatol 76(2):133–142
Winthrop KL, Baddley JW (2018) Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question. Ann Rheum Dis 77(5):631–633
Baradat C et al (2017) RMD Open 3:E352
Liao H et al (2017) Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis 20:161–168
Dixon WG et al (2011) Annals Rheum Dis 70:956–996
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M (2011) BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 50(7):1341–1342
Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB (2018) Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Baillieres Clin Rheumatol 57(6):997–1001
Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA (2007) The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57(8):1431–1438 (Dec 15)
Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737–744 (Feb 18)
Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R (2018) A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum. https://doi.org/10.1016/j.semarthrit.2018.07.006 (Jul 19. pii: S0049-0172(17)30815-6, Epub ahead of print)
Kunwar S, Collins CE, Constantinescu F (2018) Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol. https://doi.org/10.1007/s10067-018-4199-7 (Jul 13)
Droz N, Gilardin L, Cacoub P, Berenbaum F, Wendling D, Godeau B, Piette AM, Dernis E, Ebbo M, Fautrel B, Le Guenno G, Mekinian A, Bernard-Chabert B, Costedoat-Chalumeau N, Descloux E, Michot JM, Radenne S, Rigolet A, Rivière S, Yvin JL, Thibault V, Thabut D, Pol S, Guillevin L, Mouthon L, Terrier B (2013) Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (hoboken) 65(9):1504–1514 (Sep)
Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A (2018) Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med 379(5):440–453
Liao H, Zhong Z, Liu Z, Zou X (2017) Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis 20(2):161–168
Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D (2017) Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Ther Clin Risk Manag 14:2097–2111
Bartalesi F, Scirè C, Requena-Méndez A et al (2017) Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today. Clin Exp Rheumatol 35(5):752–765 (Sep–Oct; Epub 2017 May 8)
Epidemiologisches Bulletin 34/2018
Nguyen MTT, Lindegaard H, Hendricks O, Jørgensen CS, Kantsø B, Friis-Møller N (2017) Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial. J Rheumatol 44(12):1794–1803
Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, Kozuru H, Jiuchi Y, Matsumura R, Suematsu E, Miyamura T, Mori S, Fukui T, Izumi Y, Iwanaga N, Tsutani H, Saisyo K, Yamanaka T, Ohshima S, Mori N, Matsumori A, Takahi K, Yoshizawa S, Kawabe Y, Suenaga Y, Ozawa T, Hamada N, Komiya Y, Matsui T, Furukawa H, Oishi K (2015) Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther 10;17:357 (Dec)
Park JK, Lee YJ, Shin K et al (2018) Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 77(6):898–904
Epidemiologisches Bulletin 36/37 vom 9. Sept. 2013
Feuchtenberger M, Kleinert S, Schwab S, Roll P, Scharbatke EC, Ostermeier E, Voll RE, Schäfer A, Tony HP (2012) Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int 32(6):1533–1539 (Jun)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
H.-M. Lorenz und C. Kneitz geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Redaktion
H.-M. Lorenz, Heidelberg
K. Krüger, München
Rights and permissions
About this article
Cite this article
Lorenz, HM., Kneitz, C. Infektionen. Z Rheumatol 78, 236–242 (2019). https://doi.org/10.1007/s00393-018-0586-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-018-0586-3